Ubs Group Ag Unicycive Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1 shares of UNCY stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 1 -0.0%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.4 - $1.46 $1,754 - $6,403	-4,386 Reduced 99.98%	1 $0
Q1 2024 May 13, 2024	BUY	$0.83 - $1.79 $3,495 - $7,537	4,211 Added 2392.61%	4,387 $6,000
Q4 2023 Feb 09, 2024	SELL	$0.49 - $0.92 $265 - $498	-542 Reduced 75.49%	176 $0
Q3 2023 Nov 09, 2023	SELL	$0.61 - $1.31 $275 - $590	-451 Reduced 38.58%	718 $0
Q2 2023 Aug 11, 2023	BUY	$1.24 - $2.23 $1,449 - $2,606	1,169 New	1,169 $1,000
Q3 2022 Nov 10, 2022	SELL	$0.57 - $0.9 $1,881 - $2,970	-3,301 Reduced 73.5%	1,190 $1,000
Q2 2022 Aug 10, 2022	BUY	$0.7 - $1.33 $3,143 - $5,973	4,491 New	4,491 $4,000
Q1 2022 May 16, 2022	SELL	$1.07 - $2.28 $5,642 - $12,022	-5,273 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.81 - $3.05 $8,420 - $14,188	4,652 Added 749.11%	5,273 $11,000
Q3 2021 Nov 15, 2021	BUY	$2.47 - $5.85 $1,533 - $3,632	621 New	621 $2,000

Others Institutions Holding UNCY

# of Institutions

Shares Held

46.8M

Call Options Held

Put Options Held

Octagon Capital Advisors LP New York, NY

8.56M
Shares

$5.91 Million
0.85% of portfolio
Great Point Partners LLC Greenwich, CT

8.56M
Shares

$5.91 Million
1.62% of portfolio
Logos Global Management LP San Francisco, CA

5.08M
Shares

$3.5 Million
0.28% of portfolio
Walleye Capital LLC Plymouth, MN

5M
Shares

$3.45 Million
0.0% of portfolio
Vivo Capital, LLC Palo Alto, CA

4.47M
Shares

$3.08 Million
0.27% of portfolio

View Full List

About Unicycive Therapeutics, Inc.

Ticker UNCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,052,500
Market Cap $10.4M
Description
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...

More about UNCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account